Expand all sections

Bimekizumab

Extended indication Psoriasis
Therapeutic value No judgement
Total cost 6,125,000.00
Registration phase Clinical trials

Product

Active substance Bimekizumab
Domain Chronic immune diseases
Main indication Skin diseases
Extended indication Psoriasis
Manufacturer UCB
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)
Additional remarks Monoclonaal anti-lichaam gericht tegen IL-17A en IL-17F.

Registration

Registration route Centralised (EMA)
Particularity New medicine
Submission date 2019
Expected Registration 2020
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Brodalumab, Ixekizumab, Secukinumab, Ustekinumab
Therapeutic value No judgement
Duration of treatment continuous

Expected patient volume per year

Patient volume

350

Market share is generally not included unless otherwise stated.
Additional remarks Komt in principe beschikbaar voor alle patiënten met matige tot ernstige psoriasis, in Nederland zijn dat er ca. 165.000. Middel zal zijn plek moeten veroveren ten opzichte van andere reeds aanwezige biologicals. Verwachting is een paar honderd patiënten. Aantallen afhankelijk van toekomstig label.

Expected cost per patient per year

Cost 15,000.00 - 20,000.00
References Medicijnkosten.nl; Farmacotherapeutisch Kompas
Additional remarks Prijs gebaseerd op inschattingen van andere biologicals met dezelfde indicatie (Brodalumab, Ixekizumab, Secukinumab, Ustekinumab).

Potential total cost per year

Total cost

6,125,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Psoriatis arthritis; Ankylosing spondylitis
References UCB pipeline

Other information

There is currently no futher information available.